Replies to post #238166 on Anavex Life Sciences Corp (AVXL)

[anders2211]

again let me repeat:

I think they would sit on 273 until there is undeniable evidence and then offer many billions rather than now a few 100 million now that the paper is published.

Also I think Biogen will not invest in 273 for MS until after they have concluded that their Opicinumab is not working...

Biogens decision has zero to do with how well 273 works on paper for MS.